The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...

Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

Expansion into the supply chain side of the drug industry is ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...

Now that the election is over and Congress is in its lame duck session, one of the most pressing issues is reforming the abusive PBM industry ... the pharmaceutical supply chain for their own ...

PBMs are middlemen in the drug supply chain. In theory ... health care as if it’s primarily about individual bias. But the PBM system shows how neutral-seeming market structures can perpetuate ...